ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients - Launching Q1 2025 NASHUA, N.H., Nov. 26, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD) ("iCAD” or the "Company”), a global leader in clinically proven AI-powered cancer detection solutions, will showcase its groundbreaking breast health AI technologies at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, December 1-5. Key highlights include the recent FDA-cleared ProFound Detection Version 4, clinical research presentations, and a new partnership with Cascaid Health to expand access to AI-driven breast health solutions. iCAD and Cascaid Health Partner to Expand Access to AI-Driven Breast Health In alignment with their vision to enable all women to access to AI-powered breast health services, iCAD and Cascaid Health will unveil their collaboration to integrate the ProFound AI Breast Health Suite into Cascaid's leading edge digital health marketplace and access to care platform. Scheduled for beta launch in Q1 2025, this partnership between iCAD and Cascaid Health will launch ProFound Health, a virtual care model powered by Cascaid. ProFound will enable women who have not otherwise received an AI-read on their screening mammogram to access iCAD's advanced breast health technology. The initiative reflects both companies' dedication to democratizing access to life-saving technology and creating a world where cancer can't hide. ProFound Health will offer a "Second Read” virtual AI service, providing patients without access to AI an opportunity to receive enhanced breast health insights. The initial service will include second-read detection, breast density assessment, and cancer risk evaluation from a Cascaid-affiliated specialist network of clinical experts in women's health through Cascaid's seamlessly integrated digital platform. By combining AI insights with expert clinical reviews, ProFound Health ensures that patients everywhere, regardless of location, can receive precision screening and personalized care. "ProFound Health empowers patients with access to critical information about their mammograms and overall breast health, allowing them to make informed decisions and take control of their care journey,” said Dana Brown, CEO and President of iCAD. "Our collaboration with Cascaid Health's network of clinicians and AI-powered solutions is part of our ongoing commitment to bridging gaps in breast cancer care, ensuring all patients everywhere can access the accuracy and timeliness of AI solutions, and ultimately transforming patient outcomes.” "We believe that every woman should have access to the best possible information about her breast health and a high quality, personalized care plan to catch cancer early or prevent it altogether. Through our partnership with iCAD, we're addressing a critical need to improve access to advanced breast health services,” said Dr. Candace Westgate, Director of Women's Health for Cascaid Health. "ProFound Health is more than just a technological innovation, it's a lifeline that empowers patients and healthcare providers with actionable insights, bridging care gaps and ensuring equitable access to precision screening and personalized breast cancer care.” Advancing Next Generation AI Breast Health Solutions at RSNA 2024 In addition to ProFound Health, iCAD will feature its flagship ProFound Detection Version 4.0, which recently received FDA clearance. This next-generation AI solution enhances breast cancer detection by incorporating prior exams into current analysis, improving the detection of aggressive cancers by 22%, reducing cases with no marks by 18%, and providing clinicians with more reliable insights for better decision-making. "Every two minutes, someone loses their life to breast cancer-a disease affecting over 2.3 million women annually. Early detection is critical, as five-year survival rates exceed 99% for stage 1 disease. Yet traditional mammography misses over 20% of breast cancers, particularly in dense tissue, resulting in potentially avoidable late-stage diagnoses,” said Dana Brown, President and CEO of iCAD, Inc. "ProFound Detection Version 4 revolutionizes breast cancer detection by uniquely integrating prior exams into its analysis. This advanced capability enhances sensitivity, sharpens precision, and provides radiologists with a deeper, longitudinal view of a patient's breast health. By enabling earlier and more accurate detection, especially in dense tissue, ProFound Detection Version 4 sets a new standard in breast health AI, empowering providers to improve outcomes and save lives. Together with our strategic partnerships, we are advancing the fight against cancer and making a meaningful difference for patients worldwide.” ICAD'S RSNA 2024 Program Highlights AI-Powered Insights: Advancing Cancer Detection iCAD will be hosting a customer appreciation event, "AI in the Sky: Discover ProFound Insights & Breast Health Innovations," on Sunday, December 1, at 6:00 PM at VU Rooftop in Chicago. Network with industry experts, hear insights from key opinion leaders including iCAD's CEO and Board of Directors, and explore how iCAD's solutions are transforming breast health. Visit the iCAD RSNA 2024 event page for the latest updates, event details, and partnership announcements. About Cascaid Health Cascaid Health Inc. delivers a personalized, expert-driven proactive and preventative approach, supported by an integrated platform designed to promote longevity, detect issues early, reverse risks, and optimize healthspan for all. The company's platform offers a curated marketplace featuring innovative products, services, and access to world-class multidisciplinary experts in women's health, precision health, lifestyle medicine, wellness, and performance. Cascaid Health Inc. is committed to advancing health equity, ensuring that cutting-edge healthcare solutions are accessible to everyone. About iCAD, Inc. iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com . Forward-Looking Statements Certain statements contained in this News Release constitute "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe,” "demonstrate,” "intend,” "expect,” "estimate,” "will,” "continue,” "anticipate,” "likely,” "seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC's website at http://www.sec.gov . CONTACTS Media Inquiries: [email protected] Investor Inquiries: John Nesbett/Rosalyn Christian IMS Investor Relations [email protected]
Fox News loses bid for Smartmatic voting-tech company's records about Philippines bribery caseHumble running back spreads credit for success around after historic performance against the Rams.Raw milk nearly killed her son. Now avian flu is bringing more attention to its risk
The charter should be amended section by section to avoid having to conduct a referendum, as the focus should be on forming an assembly to redraft the constitution, according to legal experts. Wissanu Krea-ngam, a former deputy prime minister and prominent legal expert, said the referendum presents what look to be insurmountable legal and technical hurdles in passing a wholesale constitutional amendment within the current term of the House of Representatives. The bill to prepare the groundwork for a referendum appears to be giving lawmakers more trouble than they need, he pointed out. At least three referendums, as ruled by the Constitutional Court, must be organised with an approval vote before major changes can be made to the charter. With the House's term set to expire in less than three years, concern is growing that the process of arranging the referendums that mandate sweeping charter amendment and rewriting the constitution cannot be completed in time. Mr Wissanu said the best option was to rewrite the charter section by section, which does not require a referendum. However, it stipulates which sections or chapters in the charter necessitate a referendum if they were to be modified. "If we go down the path of a referendum, we are bound to run into a debate about how many must conducted. "Be specific and rewrite the sections that are urgent or necessary and keep well clear of the referendum-required sections. If this is done, the charter amendment might be finished in time," he said. Nikorn Chamnong, a list MP of the Chartthaipattana Party and secretary of the House-Senate referendum committee said the window was closing on organising two referendums and amending the charter within the tenure of the current House. Two referendums would defy the Constitutional Court ruling, and for that reason, he believed few lawmakers would support it. He said a viable alternative was for a bill to be tabled to amend Section 256, paving the way for a constitution-rewriting assembly to be set up to accommodate section-by-section changes. The bill could be submitted to parliament by January and take effect by March 2027, he said.Donald Trump's Financial Legacy: Nominations and Economic AgendaMANCHESTER, England (AP) — Liverpool’s lead at the top of the Premier League was cut to seven points after a thrilling 3-3 draw with Newcastle on Wednesday. Chelsea moved up to second by thrashing last-place Southampton 5-1, while Arsenal is third after a 2-0 win over Manchester United. Fourth-place Manchester City ended its seven-game winless run with a 3-0 victory over Nottingham Forest. Liverpool’s result will give hope to its title rivals after Fabian Schar’s 90th-minute equalizer at St James’ Park. Arne Slot’s team had twice come back from a goal down to take the lead in the 83rd through Mohamed Salah’s second goal of the match. But the Merseyside club was denied an eighth-straight win in all competitions when Newcastle produced a fightback of its own. “I have mixed feelings, we were outstanding in the second half, but we were not good enough in the first half," Slot said. “Maybe 3-3 is what the game deserved.” Chelsea and Arsenal took advantage. Chelsea's third league win in a row puts it ahead of Arsenal on goal difference. City also reduced the gap and is nine points behind Liverpool after finally ending the worst run of results of Pep Guardiola’s managerial career. “We needed it. The club, the players, everyone needed to win,” Guardiola said. After wins over Real Madrid and City last week, Liverpool’s title credentials were given a stern test by Newcastle, which led at halftime through Alexander Isak and again in the second half through Anthony Gordon. Goals from Curtis Jones and Salah twice leveled the game before Salah looked to have sealed the win late on. Schar equalized after Liverpool goalkeeper Caoimhin Kelleher misjudged a late free kick. It meant Liverpool dropped points for only the third time this season after drawing against Arsenal and losing to Forest. Chelsea head coach Enzo Maresca said this week that his team was not in the title race, but the standings tell a different story. The London club is Liverpool’s closest challenger after its latest win against 10-man Southampton. Axel Disasi, Christopher Nkunku, Noni Madueke, Cole Palmer and Jadon Sancho were all on target in the rout at St Mary’s Stadium. Southampton had briefly leveled the game through Joe Aribo, but Chelsea was already 3-1 up and in control when Jack Stephens was sent off before the break. Arsenal inflicted a first loss on new United head coach Ruben Amorim with a 2-0 win at the Emirates Stadium. Two goals from second-half corners made the difference, with Jurrien Timber and William Saliba finding the back of the net, but Arsenal still slipped to third, despite edging closer to Liverpool. Mikel Arteta's team finished runner-up in each of the last two seasons and looks primed to challenge again after making an unconvincing start to the campaign. “You get written off but we stuck together as a group," Arsenal midfielder Declan Rice said. “You stick together and we’re starting to reap the rewards of that.” Making his first start since September, Kevin De Bruyne showed City exactly what it has been missing by scoring a goal and creating another as the four-time defending champion got back to winning ways. The Belgium playmaker provided the cross for Bernardo Silva to give City an eighth-minute lead against Forest at the Etihad Stadium. He produced a trademark finish to sweep the ball past goalkeeper Matz Sels in the 31st to put City on course for a first win in eight games. Jeremy Doku made it 3-0 in the 57th, but it was De Bruyne’s performance that stood out after seeing much of his season disrupted by a groin injury. He left the field in the 74th to an ovation from the home crowd. “It’s been a tough time but you have to accept the challenge and I think we did well today," De Bruyne said. "The Premier League is getting harder and harder. We have to improve as a team first and we’ll see in a couple of months where we are. Hopefully, we would have improved a bit and are a lot closer.” But victory could have come at a cost with concerns over the fitness of Manuel Akanji and Nathan Ake, who both went off. “Nathan doesn’t look good. We (will) see tomorrow,” Guardiola said. “Manu is making the last two months struggle a lot.” A first win in six games for Everton moved Sean Dyche’s team further away from the relegation zone, while back-to-back losses for Wolverhampton left the club second from bottom of the standings. Ashley Young and Orel Mangala put Everton in control before two second-half own goals from Craig Dawson sealed a 4-0 win for the Merseyside club, which is five points clear of the bottom three. Aston Villa ended an even longer winless run by beating Brentford 3-1 to secure a first victory in nine games in all competitions. Morgan Rogers, Ollie Watkins from the penalty spot and Matty Cash were on target. James Robson is at https://twitter.com/jamesalanrobson AP soccer: https://apnews.com/hub/soccer
Friendly reminder |
The authenticity of this information has not been verified by this website and is for your reference only. Please do not reprint without permission. If authorized by this website, it should be used within the scope of authorization and marked with "Source: this website". |
Special attention |
Some articles on this website are reprinted from other media. The purpose of reprinting is to convey more industry information, which does not mean that this website agrees with their views and is responsible for their authenticity. Those who make comments on this website forum are responsible for their own content. This website has the right to reprint or quote on the website. The comments on the forum do not represent the views of this website. If you need to use the information provided by this website, please contact the original author. The copyright belongs to the original author. If you need to contact this website regarding copyright, please do so within 15 days. |